Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levomenol→

Levomenol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
23089-26-1
Molecular formula
C15H26O
Molecular weight
222.37 g/mol
Drug class
Topical bisabolol sesquiterpene alcoholskin-conditioning and anti-inflammatory agent
Mechanism of action
Levomenol (alpha-bisabolol) is a naturally occurring sesquiterpene alcohol with reported local anti-inflammatory, soothing and skin-conditioning properties. Proposed activities include modulation of inflammatory mediator release and enhancement of skin-barrier recovery.
Indications / reported uses
  • Used as a topical skin-conditioning and soothing ingredient in dermatological and cosmetic preparations; clinical indications depend on the specific product and formulation. It is not a systemic therapeutic API.

Sources: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=levomenol&lang=eng · https://pubchem.ncbi.nlm.nih.gov/#query=levomenol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levomenol Environmental Risk Assessment (ERA) (the Levomenol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.